Focused On-demand Library for Testis-specific serine/threonine-protein kinase 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Serine/threonine-protein kinase 22E

Alternative UPACC:

Q6SA08; Q2TA60; Q6ZNM2


Testis-specific serine/threonine-protein kinase 4, alternatively known as Serine/threonine-protein kinase 22E, plays a crucial role in male germ cell development and mature sperm function. This kinase is implicated in the Cre/Creb signaling pathway, phosphorylating CREB1 on 'Ser-133' and CREM on 'Ser-116', thereby potentially enhancing the Cre/Creb pathway's activity in cells. Its involvement extends to phosphorylating ODF2 on 'Ser-95', highlighting its significance in cellular signaling processes.

Therapeutic significance:

Understanding the role of Testis-specific serine/threonine-protein kinase 4 could open doors to potential therapeutic strategies, particularly in the realm of reproductive health and male fertility. Its pivotal role in sperm function and development positions it as a key target for addressing male infertility issues.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.